

Afectación ocular	Casos	Bilateral TCS	OCS	MD of OCS (mg/d)	IVMP	IS convencionales	MTX	AZA	CFM	MMF
Superficie	3 (7,3%)	0 (0%)	2 (66,7%)	2 (66,7%)	2 (66,7%)	2 66,7%)	2 (66,7%)	2 (66,7%)	1 (33,3%)	0 (0%)

CG/N	1 (33,3%)	0 (0%)	1 (100%)	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PUK	2 (66,7%)	0 (0%)	1 (50%)	2 (100%)	60	2 (100%)	2 (100%)	2 (100%)	2 (100%)	1 (50%)	0 (0%)
Uveítis	34 (82,9%)	8 (23,5%)	25 (73,5%)	28 (82,3%)		10 (29,4%)	19 (55,6%)	18 (52,9%)	7 (20,6%)	1 (2,9%)	1 (2,9%)
Uveítis anterior	18 (52,9%)	6 (33,3%)	11 (61,1%)	13 (72,2%)	30	1 (5,5%)	5 (27,8%)	5 (27,8%)	1 (5,5%)	0 (0%)	0 (0%)
Uveítis posterior	4 (11,7%)	1 (25%)	2 (50%)	3 (75%)	60	1 (25%)	3 (75%)	2 (50%)	2 (50%)	0 (0%)	0 (0%)
Panuveítis	12 (35,3%)	1 (8,3%)	12 (100%)	12 (100%)	60	8 (66,7%)	11 (91,7%)	11 (91,7%)	4 (33,3%)	1 (8,3%)	1 (8,3%)
Órbita ocular	4 (9,7%)	0 (0%)	2 (50%)	3 (75%)		2 (50%)	2 (50%)	2 (50%)	2 (50%)	0 (0%)	0 (0%)
Proptosis	2 (50%)	0 (0%)	1 (50%)	1 (50%)	30	1 (50%)	1 (50%)	1 (50%)	1 (50%)	0 (0%)	0 (0%)
Estrabismo	2 (50%)	0 (0%)	1 (50%)	2 (100%)	60	1 (50%)	1 (50%)	1 (50%)	1 (50%)	0 (0%)	0 (0%)
Total	41 (100%)	8 (19,5%)	29 (70,7%)	33 (80,5%)	50 ± 15,5	14 (34,1%)	23 (56,1%)	22 (53,7%)	11 (26,9%)	2 (4,9%)	1 (2,4%)

TCS: corticosteroides tópicos; OCS: corticosteroides orales; MD: máxima dosis; IVMP: metilprednisolona periférica, IS: inmunosupresores; MTX: metotrexato; AZA: azatioprina; CFM: ciclofosfamida; MMF: micofenolato mofetil; CG/N: nódulo/granuloma conjuntival; PUK: queratitis ulcerativa periférica.

Tabla 2

Afectación ocular	Casos	TB	ADA	IFX	TCZ	GLM	ETN
Superficie	3 (7,3%)	2 (66,7%)	2 (66,7%)	2 (66,7%)	0 (0%)	0 (0%)	0 (0%)

CG/N	1 (2,4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PUK	2 (4,9%)	2 (100%)	2 (100%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)
Uveítis	34 (82,9%)	12 (35,3%)	11 (32,3%)	4 (11,8%)	3 (8,8%)	2 (5,9%)	1 (2,9%)
Uveítis anterior	18 (43,9%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Uveítis posterior	4 (9,7%)	2 (50%)	1 (25%)	0 (0%)	0 (0%)	1 (25%)	0 (0%)
Panuveítis	12 (29,3%)	10 (83,3%)	10 (83,3%)	4 (33,3%)	3 (25%)	1 (8,3%)	1 (8,3%)
Órbita ocular	4 (9,7%)	2 (50%)	1 (25%)	1 (25%)	1 (25%)	0 (0%)	0 (0%)
Proptosis	2 (4,9%)	1 (50%)	1 (50%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)
Estrabismo	2 (4,9%)	1 (33,3%)	0 (0%)	1 (33,3%)	0 (0%)	0 (0%)	0 (0%)
Total	41 (100%)	14 (34,1%)	14 (34,1%)	7 (17,5%)	3 (7,3%)	2 (4,9%)	1 (2,4%)

BT: terapia biológica; IFX: infliximab; ADA: adalimumab; ETN: etanercept; GLM: golimumab; TCZ: tocilizumab; RTX: rituximab; CG/N: nódulo/granuloma conjuntival; PUK: queratitis ulcerativa periférica.

Conclusiones: La afectación ocular en la sarcoidosis es una complicación relativamente frecuente y grave, especialmente si se presenta como panuveítis.